Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections

Drugs

Volumn 72, Issue 11, 2012, Pages 1473-1493

  Lodise, Thomas P ^a   Low, Donald E ^b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Antibacterial resistance; Aztreonam; Ceftaroline fosamil; Ceftriaxone; Clarithromycin; Community acquired pneumonia; Methicillin resistant Staphylococcus aureus infections; Skin infections; Vancomycin

Indexed keywords

AMIKACIN; AMINOTRANSFERASE; AZITHROMYCIN; AZTREONAM; BETA LACTAMASE; BETA LACTAMASE AMPC; CEFEPIME; CEFTAROLINE FOSAMIL; CEFTRIAXONE; CLARITHROMYCIN; CLASS B METALLO BETA LACTAMASE; DAPTOMYCIN; EXTENDED SPECTRUM BETA LACTAMASE; LINEZOLID; MEROPENEM; PENICILLIN G; TIGECYCLINE; TOBRAMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTERIAL PNEUMONIA; BACTERIAL SKIN DISEASE; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; BACTERIUM ISOLATE; BACTEROIDES FRAGILIS; BITE INFECTION; BURN INFECTION; CELLULITIS; CLINICAL PRACTICE; COLONY FORMING UNIT; COMMUNITY ACQUIRED PNEUMONIA; CREATININE CLEARANCE; DIARRHEA; DRUG ANTAGONISM; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCARDITIS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEADACHE; HEMODIALYSIS; HUMAN; HYPERTENSION; HYPOKALEMIA; KIDNEY FAILURE; MAXIMUM PLASMA CONCENTRATION; MENINGITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT STREPTOCOCCUS PNEUMONIAE; NAUSEA; NONHUMAN; OSTEOMYELITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CLEARANCE; PLASMA PROTEIN BINDING; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SKIN ABSCESS; SKIN INFECTION; SKIN STRUCTURE; SKIN STRUCTURE INFECTION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; ULCER INFECTION; WOUND INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CEPHALOSPORINS; CLINICAL TRIALS AS TOPIC; COMMUNITY-ACQUIRED INFECTIONS; DOUBLE-BLIND METHOD; HUMANS; PNEUMONIA, BACTERIAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN DISEASES, BACTERIAL;

BACTERIA (MICROORGANISMS); BACTEROIDES FRAGILIS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEGIBACTERIA; POSIBACTERIA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 84864228137     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11635660-000000000-00000     Document Type: Review

References (81)

1. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twentieth informational supplement (M100-S20). Wayne (PA): Clinical and Laboratory Standards Institute, 2010
2. Zhanel GG, Sniezek G, Schweizer F, et al. Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus. Drugs 2009; 69: 809-31
3. Villegas-Estrada A, Lee M, Hesek D, et al. Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA b-lactam antibiotics. J Am Chem Soc 2008; 130: 9212-3 (Pubitemid 352031115)
4. Kosowska-Shick K, McGhee PL, Appelbaum PC. Affinity of ceftaroline and other b-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.AntimicrobAgents Chemother 2010; 54: 1670-7
5. Moisan H, Pruneau M, Malouin F. Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae. J Antimicrob Chemother 2010; 65: 713-6
6. Richter SS, Heilmann KP, Dohrn CL, et al. Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from43 medical centers in the United States in 2009. Antimicrob Agents Chemother 2011; 55: 4154-60
7. Sader HS, Moet G, Jones RN. In vitro activity of ceftaroline tested against recent clinical isolates from the United States (USA) [abstract no. 894]. 47th Annual Meeting of the Infectious Diseases Society of America; 2009 Oct 29-Nov 1; Philadelphia (PA)
8. Saravolatz L, Pawlak J, Johnson L. In vitro activity of ceftaroline against community-associated methicillinresistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates. Antimicrob Agents Chemother 2010; 54: 3027-30
9. Flamm RK, Sader HS, Farrell DJ, et al. Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program. Antimicrob Agents Chemother 2012; 56: 293-4
10. Castanheira M, Jones RN, Sader HS. In vitro activity of ceftaroline tested against leading gram-positive and gram-negative European bacterial pathogens collected in 2009 [abstract no. 1876]. 20th Annual European Congress of Clinical Microbiology and Infectious Diseases; 2010 Apr 10-13; Vienna
11. Karlowsky JA,AdamHJ,DeCorbyMR, et al. In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009. Antimicrob Agents Chemother 2011; 55: 2837-46
12. TEFLARO (ceftaroline fosamil) [prescribing information]. St. Louis (MO): Forest Pharmaceuticals, Inc., 2012
13. Brown SD, Traczewski MM. In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing. Antimicrob Agents Chemother 2009; 53: 1271-4
14. Ge Y, Biek D, Talbot GH, et al. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother 2008; 52: 3398-407
15. Jacobs MR, Good CE, Windau AR, et al. Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 2010; 54: 2716-9
16. McGee L, Biek D, Ge Y, et al. In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporinresistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2009; 53: 552-6
17. Morrissey I, Ge Y, Janes R. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia. Int J Antimicrob Agents 2009; 33: 515-9
18. Patel SN, Pillai DR, Pong-Porter S, et al. In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of Streptococcus pneumoniae collected from across Canada between 2003 and 2008 [letter]. J Antimicrob Chemother 2009; 64: 659-60
19. Mushtaq S, Warner M, Ge Y, et al. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother 2007; 60: 300-11 (Pubitemid 47243878)
20. Citron DM, Tyrrell KL, Merriam CV, et al. In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria. Antimicrob Agents Chemother 2010; 54: 1627-32
21. Snydman DR, Jacobus NV, McDermott LA. In vitro activity of ceftaroline against a broad spectrum of recent clinical anaerobic isolates. Antimicrob Agents Chemother 2011; 55: 421-5
22. Schaadt RD, Sweeney DA, Biek D, et al. In vitro evaluation of the antibacterial activity of ceftaroline in combination with other antibacterial agents [abstract no. E-279]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17-21; Chicago (IL)
23. Vidaillac C, Leonard SN, Rybak MJ. In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired methicillin-resistant Staphylococcus aureus (HA-MRSA) isolates. Int J Antimicrob Agents 2010; 35: 527-30
24. Vidaillac C, Leonard SN, Sader HS, et al. In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including b-lactamase-producing Enterobacteriaceae and Pseudo- monas aeruginosa. Antimicrob Agents Chemother 2009; 53: 2360-6
25. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52 (1): 1 (Pubitemid 36850074)
26. Clark C, McGhee P, Appelbaum PC, et al. Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria. Antimicrob Agents Chemother 2011; 55: 2344-51
27. Hinshaw RR, Schaadt RD, Murray B, et al. Spontaneous mutation frequency and serial passage resistance development studies with ceftaroline (CPT) [abstract no. C1-185]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/ 46th Annual Meeting of the Infectious Diseases Society of America; 2008 Oct 25-28; Washington, DC
28. Pankuch GA, Appelbaum PC. Postantibiotic effect of ceftaroline against gram-positive organisms. Antimicrob Agents Chemother 2009; 53: 4537-9
29. Keel RA, Crandon JL, Nicolau DP. Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates. Antimicrob Agents Chemother 2011; 55: 4028-32
30. Steed M, Vidaillac C, Rybak MJ. Evaluation of ceftaroline activity versus daptomycin (DAP) against DAPnonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2011; 55: 3522-6
31. Vidaillac C, Leonard SN, Rybak MJ. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model. Antimicrob Agents Chemother 2009; 53: 4712-7
32. Zhanel GG, Rossnagel E, Nichol K, et al. Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin- resistant S. aureus using an in vitro model. J Antimicrob Chemother 2011; 66: 1301-5
33. Housman ST, Keel RA, Crandon JL, et al. Efficacy of human simulated exposures of ceftaroline against phenotypically diverse Enterobacteriaceae. Antimicrob Agents Chemother 2012; 56: 2576-80
34. Jacqueline C, Caillon J, Le Mabecque V, et al. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin- intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob Agents Chemother 2007; 51: 3397-400 (Pubitemid 350067563)
35. Jacqueline C, Amador G, Batard E, et al. Comparison of ceftaroline fosamil, daptomycin and tigecycline in an experimental rabbit endocarditis model caused by methicillinsusceptible, methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. J Antimicrob Chemother 2011; 66: 863-6
36. Jacqueline C, Caillon J, Le Mabecque V, et al. In vivo activity of a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, ceftaroline, against vancomycinsusceptible and -resistant Enterococcus faecalis strains in a rabbit endocarditis model: a comparative study with linezolid and vancomycin. Antimicrob Agents Chemother 2009; 53: 5300-2
37. Jacqueline C, Amador G, Caillon J, et al. Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis. J Antimicrob Chemother 2010; 65: 1749-52
38. Croisier-Bertin D, Piroth L, Charles PE, et al. Ceftaroline versus ceftriaxone in a highly penicillin-resistant pneumococcal pneumonia rabbit model using simulated human dosing. Antimicrob Agents Chemother 2011; 55: 3557-63
39. Cottagnoud P, Acosta F, Biek D, et al. Efficacy of ceftaroline fosamil against penicillin-sensitive and -resistant Streptococcus pneumoniae in an experimental rabbit meningitis model [abstract no. B-702]. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2010 Sep 12-15; Boston (MA)
40. Cottagnoud P, Stucki A, Acosta F, et al. Ceftaroline fosamil is superior to cefepime against a Klebsiella pneumoniae strain in an experimental rabbit meningitis model [abstract no. 1569]. 20th Annual European Congress of Clinical Microbiology and Infectious Diseases; 2010 Apr 10-13; Vienna
41. Andes D, Craig WA. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillinresistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic- pharmacodynamic target. Antimicrob Agents Chemother 2006; 50: 1376-83
42. Jones RN, Fritsche TR, Ge Y, et al. Evaluation of PPI- 0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests. J Antimicrob Chemother 2005; 56: 1047-52 (Pubitemid 43009818)
43. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-12 (Pubitemid 28068148)
44. Ishikawa T, Matsunaga N, Tawada H, et al. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. Bioorg Med Chem 2003; 11: 2427-37 (Pubitemid 36539379)
45. Ge Y, Redman R, Floren L, et al. The pharmacokinetics (PK) and safety of ceftaroline (PPI-0903M) in healthy subjects receiving multiple-dose intravenous (IV) infusions [abstract no. A-1937]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA)
46. Steed ME, Rybak MJ. Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens. Pharmacotherapy 2010; 30: 375-89
47. Ge Y, Hubbel A. In vitro evaluation of plasma protein binding and metabolic stability of ceftaroline (PPI-0903M) [abstract no. A-1935]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA)
48. Ge Y, Redman R, Floren L, et al. Single-dose pharmacokinetics (PK) of ceftaroline (PPI-0903) in healthy subjects [abstract no. A-1936]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA)
49. Van Wart SA, Reynolds DK, Khariton T, et al. Impact of concomitant medication use on the pharmacokinetics of ceftaroline in patients with complicated skin and skin structure infections or community-acquired pneumonia [abstract no. A2-548]. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2011 Sep 17-20; Chicago (IL)
50. Ge Y, Thye D, Liao S, et al. Pharmacokinetics (PK) of ceftaroline (PPI-0903) in subjects with mild or moderate renal impairment (RI) [abstract no. A-1039]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA)
51. Riccobene T, Fang E, Thye D. An open-label pharmacokinetic (PK), safety, and tolerability study of single intravenous (IV) doses of ceftaroline (CPT) in subjects with normal renal function or severe renal impairment [abstract no. A1-003]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 Sep 12-15; San Francisco (CA)
52. Riccobene T, Jakate A, Rank D, et al. An open-label, pharmacokinetic, safety and tolerability study of singledose intravenous ceftaroline in subjects with end-stage renal disease on intermittent haemodialysis [abstract no. P1455]. 19th Annual Meeting of the European Society of Clinical Microbiology and Infectious Diseases (ECCMID); 2009 May 16-19; Helsinki
53. Riccobene T, Jakate A, Rank D, et al. Open-label pharmacokinetic, safety, and tolerability study of single intravenous doses of ceftaroline in healthy elderly and healthy young adult subjects [abstract no. 3-161]. 44th Annual Midyear Meeting of the American Society of Health-System Pharmacists (ASHP); 2009 Dec 6-10; Las Vegas (NV)
54. Cerexa, Inc. Study of blood levels of ceftaroline fosamil in children who are receiving antibiotic therapy in the hospital [ClinicalTrials.gov identifier NCT01298843]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Jun 22]
55. Bhavnani SM, Van Wart SA, Rubino CM, et al. Pharmacokinetic- pharmacodynamic target attainment analysis to evaluate susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus [abstract no. A2-553]. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2011 Sep 17-20; Chicago (IL)
56. Van Wart SA, Forrest A, Khariton T, et al. Population pharmacokinetic analysis of ceftaroline in patients with complicated skin and skin structure infection or communityacquired pneumonia [abstract no. A2-547]. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2011 Sep 17-20; Chicago (IL)
57. Drusano GL. Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity. J Antimicrob Chemother 2010; 65 Suppl. 4: iv33-9
58. Corey GR, Wilcox MH, Talbot GH, et al., on behalf of the CANVAS 1 investigators. CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65 Suppl. 4: iv41-51
59. Wilcox MH, Corey GR, Talbot GH, et al., on behalf of the CANVAS 2 investigators. CANVAS 2: the second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65 Suppl. 4: iv53-65
60. Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010; 51: 641-50
61. Noel GJ, Strauss RS, Amsler K, et al. Results of a doubleblind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by grampositive bacteria. Antimicrob Agents Chemother 2008; 52: 37-44
62. Stryjewski ME, Graham DR, Wilson SE, et al., Assessment of Telavancin in Complicated Skin and Skin-Structure Infections Study. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008; 46: 1683-93 (Pubitemid 351706765)
63. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), US Department of Health and Human Services. Guidance for industry, acute bacterial skin and skin structure infections: developing drugs for treatment (draft guidance). Rockville (MD): US Dept of Health and Human Services, 2010 Aug [online]. Available from URL: http://www.fda.gov/downloads/Drugs/G uidanceComplianceRegulatoryInformation/Guidances/ucm 071185.pdf [Accessed 2011 June 2]
64. Snodgrass WR, Anderson T. Prontosil in the treatment of erysipelas, a controlled series of 312 cases. Br Med J 1937; 2: 101-4
65. Snodgrass WR, Anderson T. Sulphanilamide in the treatment of erysipelas, a controlled series of 270 cases. Br Med J 1937; 2: 1156-9
66. Friedland HD, O'Neal T, Biek D, et al. CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil vs vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 2012; 56: 2231-6
67. File TM Jr, Low DE, Eckburg PB, et al., on behalf of the FOCUS 1 investigators. FOCUS 1: a randomized, doubleblinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community- acquired pneumonia. J Antimicrob Chemother 2011; 66 Suppl. 3: iii19-32
68. Low DE, File TM Jr, Eckburg PB, et al., on behalf of the FOCUS 2 investigators. FOCUS 2: a randomized, doubleblinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community- acquired pneumonia. J Antimicrob Chemother 2011; 66 Suppl. 3: iii33-44
69. File TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, double-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community- acquired pneumonia [published erratumappears in Clin Infect Dis 2011; 52: 967]. Clin Infect Dis 2010; 51: 1395-405
70. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-50 (Pubitemid 27044625)
71. Drehobl MA, De Salvo MC, Lewis DE, et al. Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate communityacquired pneumonia in adults. Chest 2005; 128: 2230-7 (Pubitemid 41507564)
72. Gotfried MH, Dattani D, Riffer E, et al. A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia. Clin Ther 2002; 24: 736-51 (Pubitemid 34596943)
73. Tanaseanu C, Bergallo C, Teglia O, et al., 308 Study Group; 313 Study Group. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in communityacquired pneumonia. Diagn Microbiol Infect Dis 2008; 61: 329-38 (Pubitemid 351858575)
74. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), US Department of Health and Human Services. Guidance for industry, communityacquired bacterial pneumonia: developing drugs for treatment (draft guidance). Rockville (MD): US Department of Health and Human Services, 2009 Mar [online]. Available from URL: http://www.fda.gov/downloads/Drugs/Gui danceComplianceRegulatoryInformation/Guidances/ucm 123686.pdf [Accessed 2011 Jun 2]
75. Forest Laboratories, Inc. Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia and complicated skin and skin structure infections. FDA briefing document for anti-infective drugs advisory committee meeting. 2010 Sep 7 [online]. Available from URL: http://www.fda.gov/downloads/ advisorycommittees/committeesmeetingmaterials/drugs/anti- infectivedrugsadvisorycommittee/ucm224656.pdf [Accessed 2011 June 2]
76. Eckburg PB, Friedland HD, Llorens L, et al. Day 4 clinical response of ceftaroline fosamil versus ceftriaxone for community-acquired bacterial pneumonia. Infect Dis Clin Pract. Epub 2012 Jun 13
77. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of communityacquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl.: S27-72 (Pubitemid 46290553)
78. Corrado ML. Integrated safety summary of CANVAS 1 and 2 trials: phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65 Suppl. 4: iv67-71
79. Rank DR, Friedland HD, Laudano JB. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother 2011; 66 Suppl. 3: iii53-9
80. Rank DR, Baculik T, Eckburg P, et al. Integrated safety analysis of CANVAS and FOCUS studies: randomized, double-blinded, phase 3 studies of ceftaroline (CPT) fosamil versus comparators in complicated skin and skin structure infection (cSSSI) and community-acquired bacterial pneumonia (CABP) [abstract no. P1531]. 21st Annual European Congress of Clinical Microbiology and Infectious Diseases/27th International Congress on Chemotherapy; 2011 May 7-10; Milan
81. Panagiotidis G, Báckstróm T, Asker-Hagelberg C, et al. Effect of ceftaroline on normal human intestinal microflora. Antimicrob Agents Chemother 2010; 54: 1811-4